- Home
- NBTX vs OCGN Comparison
NBTX vs OCGN Comparison
Compare NBTX & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- OCGN
- Stock Information
- Founded
- NBTX 2003
- OCGN 2013
- Country
- NBTX France
- OCGN United States
- Employees
- NBTX N/A
- OCGN N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBTX Health Care
- OCGN Health Care
- Exchange
- NBTX Nasdaq
- OCGN Nasdaq
- Market Cap
- NBTX 178.7M
- OCGN 189.6M
- IPO Year
- NBTX 2020
- OCGN N/A
- Fundamental
- Price
- NBTX $3.29
- OCGN $0.68
- Analyst Decision
- NBTX Strong Buy
- OCGN Strong Buy
- Analyst Count
- NBTX 1
- OCGN 3
- Target Price
- NBTX $8.00
- OCGN $6.33
- AVG Volume (30 Days)
- NBTX 11.4K
- OCGN 4.3M
- Earning Date
- NBTX 04-02-2025
- OCGN 05-13-2025
- Dividend Yield
- NBTX N/A
- OCGN N/A
- EPS Growth
- NBTX N/A
- OCGN N/A
- EPS
- NBTX N/A
- OCGN N/A
- Revenue
- NBTX N/A
- OCGN $4,054,999.00
- Revenue This Year
- NBTX N/A
- OCGN N/A
- Revenue Next Year
- NBTX $277.81
- OCGN N/A
- P/E Ratio
- NBTX N/A
- OCGN N/A
- Revenue Growth
- NBTX N/A
- OCGN N/A
- 52 Week Low
- NBTX $2.76
- OCGN $0.52
- 52 Week High
- NBTX $7.51
- OCGN $2.06
- Technical
- Relative Strength Index (RSI)
- NBTX 46.34
- OCGN 51.84
- Support Level
- NBTX $3.28
- OCGN $0.64
- Resistance Level
- NBTX $3.53
- OCGN $0.74
- Average True Range (ATR)
- NBTX 0.18
- OCGN 0.07
- MACD
- NBTX 0.00
- OCGN 0.00
- Stochastic Oscillator
- NBTX 46.48
- OCGN 54.50
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").